A Phase 3 Randomized, Open-Label Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1
Cytogenetic Response (CyR) is based on the prevalence of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a bone marrow (BM) sample. Complete Cytogenetic Response (CCyR) was achieved when there was 0 percent (%) Ph+ metaphases among cells in a BM sample when at least 20 metaphases from a BM sample were analyzed.
Year 1
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
3160A4-3000
NCT00574873
February 2008
September 2014
Name | Location |
---|---|
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Atlanta, Georgia 30342 |
Pfizer Investigational Site | Crestview Hills, Kentucky 41017 |
Pfizer Investigational Site | Detroit, Michigan 48201 |
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Clearwater, Florida 33761 |
Pfizer Investigational Site | Carmel, Indiana 46032 |
Pfizer Investigational Site | Cedar Rapids, Iowa 52403 |
Pfizer Investigational Site | Kansas City, Kansas 66112 |
Pfizer Investigational Site | Westminster, Maryland 21157 |
Pfizer Investigational Site | Santa Fe, New Mexico 87505 |
Pfizer Investigational Site | Bristol, Tennessee 37620 |
Pfizer Investigational Site | Livingston, New Jersey 07039 |